Dandekar Atul 4
4 · Maze Therapeutics, Inc. · Filed Dec 31, 2025
Insider Transaction Report
Form 4
Dandekar Atul
CSBO
Transactions
- Exercise/Conversion
Common Stock
2025-12-29$10.42/sh+72,400$754,408→ 82,903 total - Sale
Common Stock
2025-12-29$40.51/sh−66,365$2,688,552→ 16,538 total - Sale
Common Stock
2025-12-29$41.13/sh−6,035$248,211→ 10,503 total - Exercise/Conversion
Common Stock
2025-12-30$10.42/sh+100$1,042→ 10,603 total - Sale
Common Stock
2025-12-30$40.36/sh−100$4,036→ 10,503 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-29−72,400→ 74,243 totalExercise: $10.42Exp: 2031-04-11→ Common Stock (72,400 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-30−100→ 74,143 totalExercise: $10.42Exp: 2031-04-11→ Common Stock (100 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- [F2]The reported total includes 1,562 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.99 to $40.985 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.51 per share, inclusive.
- [F5]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.